Editorial Material; Comment on Prognostic Impact of a 12-gene Progression Score in Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Validation Study. [Eur Urol. 2017
Purpose Use of molecular markers in urine, tissue or blood offers potential opportunities to improv...
Bladder cancer is a heterogeneous disease that is not depicted by current classification systems. It...
In bladder cancer, clinical grade and stage fail to capture outcome. We developed a clinically appli...
UnrestrictedUrothelial carcinoma of the urinary bladder is the seventh most common type of cancer wo...
OBJECTIVES: To summarize the current status of clinicopathological and molecular markers for the pre...
© Translational Andrology and Urology. Bladder cancer (BC) is a common disease in both sexes and maj...
Urothelial bladder carcinoma (UBC) is an intricate malignancy with a variable natural history and cl...
Non-muscle invasive bladder cancer (BCa) is the second most common genitourinary malignancy, burdene...
BACKGROUND: Multiple clinical risk factors and genetic profiles have been demonstrated to predict pr...
textabstractBackground: Multiple clinical risk factors and genetic profiles have been demonstrated t...
PURPOSE: To evaluate performances of published gene signatures for the assessment of urothelial carc...
International audiencePURPOSE OF REVIEW:Despite that nearly 75% of bladder cancer patients are diagn...
Bladder cancer tumors can be divided into two molecular subtypes referred to as luminal or basal. Ea...
Bladder cancer (BC) is one of the most expensive lifetime cancers to treat because of the high recur...
International audienceThis study evaluated the prognostic value of a panel of 29 oncogenes derived f...
Purpose Use of molecular markers in urine, tissue or blood offers potential opportunities to improv...
Bladder cancer is a heterogeneous disease that is not depicted by current classification systems. It...
In bladder cancer, clinical grade and stage fail to capture outcome. We developed a clinically appli...
UnrestrictedUrothelial carcinoma of the urinary bladder is the seventh most common type of cancer wo...
OBJECTIVES: To summarize the current status of clinicopathological and molecular markers for the pre...
© Translational Andrology and Urology. Bladder cancer (BC) is a common disease in both sexes and maj...
Urothelial bladder carcinoma (UBC) is an intricate malignancy with a variable natural history and cl...
Non-muscle invasive bladder cancer (BCa) is the second most common genitourinary malignancy, burdene...
BACKGROUND: Multiple clinical risk factors and genetic profiles have been demonstrated to predict pr...
textabstractBackground: Multiple clinical risk factors and genetic profiles have been demonstrated t...
PURPOSE: To evaluate performances of published gene signatures for the assessment of urothelial carc...
International audiencePURPOSE OF REVIEW:Despite that nearly 75% of bladder cancer patients are diagn...
Bladder cancer tumors can be divided into two molecular subtypes referred to as luminal or basal. Ea...
Bladder cancer (BC) is one of the most expensive lifetime cancers to treat because of the high recur...
International audienceThis study evaluated the prognostic value of a panel of 29 oncogenes derived f...
Purpose Use of molecular markers in urine, tissue or blood offers potential opportunities to improv...
Bladder cancer is a heterogeneous disease that is not depicted by current classification systems. It...
In bladder cancer, clinical grade and stage fail to capture outcome. We developed a clinically appli...
DOI